Vera Therapeutics, Inc. Share Price & Technical Analysis
VERA · $31.62 (-0.60%)
Healthcare / Biotechnology
$31.62
-0.60%
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous inj…
Price chart
Seasonality
Jun has 1 positive and 4 negative years (last 5 years shown)
-10% return in Jun, 19% avg return in past 3 year Jun month.
-43% return in 2026, 68% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -15% | -5% | 1% | -14% | 1% | -10% | – | – | – | – | – | – | -43% |
| 25 | -12% | -18% | -20% | -3% | -19% | -26% | -11% | 3% | 33% | -2% | 20% | 52% | -2% |
| 24 | 139% | 29% | -10% | -8% | -4% | -8% | 1% | 3% | 15% | -8% | 23% | -15% | 157% |
| 23 | -56% | -13% | 5% | -14% | 25% | 90% | 18% | -6% | -23% | -24% | 31% | 15% | 49% |
| 22 | -27% | 16% | 0% | -15% | -31% | -7% | 26% | 28% | 0% | -13% | -11% | 18% | -16% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.32B
P/E ratio
—
52W high
$56.05
52W low
$19.07
Volume
6,78,331
Beta
0.95
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Vera Therapeutics, Inc. share price today?
- Vera Therapeutics, Inc. (VERA) last traded around $31.62 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VERA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VERA. Download the app for real-time alerts.
- How can I analyze Vera Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.